Thymic expression of a T-cell receptor targeting a tumor-associated antigen coexpressed in the thymus induces T-ALL

Blood

Volumn 125, Issue 19, 2015, Pages 2958-2967

  Cui, Yongzhi ^a   Onozawa, Masahiro ^a   Garber, Haven R ^a   Samsel, Leigh ^b   Wang, Ziyao ^a   McCoy, J Philip ^b   Burkett, Sandra ^c   Wu, Xiaolin ^d   Aplan, Peter D ^a   Mackall, Crystal L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

Thymic expression of signaling receptors targeting taas coexpressed in the thymus poses a risk for leukemogenesis; Thymocyte signaling via a transgenic survivin reactive tcr induced t all with 100 penetrance

Indexed keywords

CYCLOSPORIN A; GENOMIC DNA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NOTCH1 RECEPTOR; PEPTIDE DERIVATIVE; SHORT HAIRPIN RNA; SURVIVIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR NFAT; TUMOR ANTIGEN; BIRC5 PROTEIN, MOUSE; CELL ADHESION MOLECULE; HOMEODOMAIN PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; MESSENGER RNA; PEPTIDE FRAGMENT; RAG-1 PROTEIN; REPRESSOR PROTEIN; TAA1 PROTEIN, MOUSE; TUMOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELIC EXCLUSION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL MATURATION; CELL SURVIVAL; CELL VIABILITY; CHROMOSOME 11; CHROMOSOME 14; COMPARATIVE STUDY; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENOMIC INSTABILITY; HETEROZYGOTE; IMMUNOFLUORESCENCE; LEUKEMIA CELL LINE; LEUKEMOGENESIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; ONCOGENE; PENETRANCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SPLEEN CELL; T CELL ACUTE LYMPHOBLASTIC LEUKEMIA; T CELL LEUKEMIA; T LYMPHOCYTE ACTIVATION; THYMOCYTE; THYMUS; ANIMAL; C57BL MOUSE; CELL TRANSFORMATION; CYTOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CELL ADHESION MOLECULES; CELL TRANSFORMATION, NEOPLASTIC; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HOMEODOMAIN PROTEINS; INHIBITOR OF APOPTOSIS PROTEINS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, T-CELL; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; THYMUS GLAND; TUMOR CELLS, CULTURED;

EID: 84947344019     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-10-609271     Document Type: Article

References (52)

1. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917-924.
2. Johnson LA, Heemskerk B, Powell DJ Jr, et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumorinfiltrating lymphocytes. J Immunol. 2006;177(9): 6548-6559.
3. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009; 114(3):535-546.
4. Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36(2):133-151.
5. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra225.
6. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukemia in children and young adults: a phase 1 doseescalation trial. Lancet. 2015;385(9967):517-528.
7. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16): 1507-1517.
8. Cameron BJ, Gerry AB, Dukes J, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013; 5(197):197ra103.
9. Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863-871.
10. Lamers CH, Sleijfer S, van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21(4):904-912.
11. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843-851.
12. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16): 1509-1518.
13. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2): 188-195.
14. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415-419.
15. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132-3142.
16. Williams DA, Thrasher AJ. Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases. Stem Cells Transl Med. 2014;3(5):636-642.
17. Aiuti A, Cassani B, Andolfi G, et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest. 2007;117(8): 2233-2240.
18. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12(4):401-409.
19. Woods NB, Bottero V, Schmidt M, von Kalle C, Verma IM. Gene therapy: therapeutic gene causing lymphoma. Nature. 2006;440(7088): 1123.
20. Davé UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science. 2004;303(5656):333.
21. Scobie L, Hector RD, Grant L, et al. A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity [published correction appears in Mol Ther. 2009 Aug;17(8): 1483]. Mol Ther. 2009;17(6):1031-1038.
22. Blüthmann H, Kisielow P, Uematsu Y, et al. T-cellspecific deletion of T-cell receptor transgenes allows functional rearrangement of endogenous alpha- and beta-genes. Nature. 1988;334(6178): 156-159.
23. Brabb T, Rubicz R, Mannikko V, Goverman J. Separately expressed T cell receptor alpha and beta chain transgenes exert opposite effects on T cell differentiation and neoplastic transformation. Eur J Immunol. 1997;27(11): 3039-3048.
24. dos Santos NR, Rickman DS, de Reynies A, et al. Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia. Blood. 2007;109(9):3972-3981.
25. Serwold T, Hochedlinger K, Swindle J, Hedgpeth J, Jaenisch R, Weissman IL. T-cell receptordriven lymphomagenesis in mice derived from a reprogrammed T cell. Proc Natl Acad Sci USA. 2010;107(44):18939-18943.
26. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008;118(9):3143-3150.
27. Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer. 2012;12(10):671-684.
28. Gschweng E, De Oliveira S, Kohn DB. Hematopoietic stem cells for cancer immunotherapy. Immunol Rev. 2014;257(1): 237-249.
29. Andersen MH, Svane IM, Becker JC, Straten PT. The universal character of the tumor-associated antigen survivin. Clin Cancer Res. 2007;13(20): 5991-5994.
30. Zhumabekov T, Corbella P, Tolaini M, Kioussis D. Improved version of a human CD2 minigene based vector for T cell-specific expression in transgenic mice. J Immunol Methods. 1995; 185(1):133-140.
31. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigenspecific CD81 T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003; 281(1-2):65-78.
32. Kobayashi K, Hatano M, Otaki M, Ogasawara T, Tokuhisa T. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc Natl Acad Sci USA. 1999;96(4): 1457-1462.
33. Holler PD, Lim AR, Cho BK, Rund LA, Kranz DM. CD8(-) T cell transfectants that express a high affinity T cell receptor exhibit enhanced peptidedependent activation. J Exp Med. 2001;194(8): 1043-1052.
34. Zeh HJ III, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two selfantigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol. 1999;162(2): 989-994.
35. Corse E, Gottschalk RA, Allison JP. Strength of TCR-peptide/MHC interactions and in vivo T cell responses. J Immunol. 2011;186(9):5039-5045.
36. Petrie HT, Livak F, Schatz DG, Strasser A, Crispe IN, Shortman K. Multiple rearrangements in T cell receptor alpha chain genes maximize the production of useful thymocytes. J Exp Med. 1993;178(2):615-622.
37. Malissen M, Trucy J, Letourneur F, et al. A T cell clone expresses two T cell receptor alpha genes but uses one alpha beta heterodimer for allorecognition and self MHC-restricted antigen recognition. Cell. 1988;55(1):49-59.
38. Borgulya P, Kishi H, Uematsu Y, von Boehmer H. Exclusion and inclusion of alpha and beta T cell receptor alleles. Cell. 1992;69(3):529-537.
39. Kelly KA, Pircher H, von Boehmer H, Davis MM, Scollay R. Regulation of T cell production in T cell receptor transgenic mice. Eur J Immunol. 1993; 23(8):1922-1928.
40. Nikolí-ZugíJ, Andjelí S, Teh HS, Jain N. The influence of rearranged T cell receptor alpha beta transgenes on early thymocyte development. Eur J Immunol. 1993;23(7):1699-1704.
41. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004; 306(5694):269-271.
42. Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest. 2012;122(10):3398-3406.
43. Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes. Nat Genet. 1999;23(4):387-388.
44. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009; 15(17):5323-5337.
45. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3(1): 46-54.
46. Leisegang M, Wilde S, Spranger S, et al. MHCrestricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J Clin Invest. 2010;120(11):3869-3877.
47. Glas R, Franksson L, Ohlén C, et al. Major histocompatibility complex class I-specific and -restricted killing of beta 2-microglobulindeficient cells by CD8+ cytotoxic T lymphocytes. Proc Natl Acad Sci USA. 1992;89(23):11381-11385.
48. Glas R, Ohlén C, Höglund P, Kärre K. The CD81 T cell repertoire in beta 2-microglobulin-deficient mice is biased towards reactivity against selfmajor histocompatibility class I. J Exp Med. 1994; 179(2):661-672.
49. Felli MP, Vacca A, Calce A, et al. PKC theta mediates pre-TCR signaling and contributes to Notch3-induced T-cell leukemia. Oncogene. 2005;24(6):992-1000.
50. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD81 T cells. J Clin Invest. 2005;115(6):1616-1626.
51. Newrzela S, Cornils K, Li Z, et al. Resistance of mature T cells to oncogene transformation. Blood. 2008;112(6):2278-2286.
52. Bessette K, Lang ML, Fava RA, et al. A Stat5b transgene is capable of inducing CD81 lymphoblastic lymphoma in the absence of normal TCR/MHC signaling. Blood. 2008;111(1): 344-350.